Compare · MRNA vs RXRX
MRNA vs RXRX
Side-by-side comparison of Moderna Inc. (MRNA) and Recursion Pharmaceuticals Inc. (RXRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRNA and RXRX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $18.89B, about 10.7x RXRX ($1.76B).
- Over the past year, MRNA is up 67.0% and RXRX is down 40.1% - MRNA leads by 107.1 points.
- MRNA has been more active in the news (15 items in the past 4 weeks vs 12 for RXRX).
- MRNA has more recent analyst coverage (25 ratings vs 10 for RXRX).
- Company
- Moderna Inc.
- Recursion Pharmaceuticals Inc.
- Price
- $47.01-1.26%
- $3.21-3.02%
- Market cap
- $18.89B
- $1.76B
- 1M return
- -13.53%
- -3.31%
- 1Y return
- +67.01%
- -40.13%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2021
- News (4w)
- 15
- 12
- Recent ratings
- 25
- 10
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. It has four clinical-stage drug candidates focused on rare, monogenic diseases; and 33 additional programs in various stages of preclinical development. Recursion Pharmaceuticals, Inc. has strategic agreements with Bayer; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. The company was founded in 2013 and is based in Salt Lake City, Utah.
Latest MRNA
- Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome
- Chief Legal Officer Klinger Shannon Thyme exercised 15,269 shares at a strike of $7.04, sold $173,550 worth of shares (3,471 units at $50.00) as part of a pre-agreed trading plan and covered exercise/tax liability with 5,705 shares, increasing direct ownership by 9% to 73,561 units (SEC Form 4) to cover withholding tax
- Chief Financial Officer Mock James M converted options into 11,798 shares and covered exercise/tax liability with 5,705 shares, increasing direct ownership by 10% to 65,687 units (SEC Form 4) to satisfy tax liability
- Chief Financial Officer Mock James M converted options into 2,475 shares and covered exercise/tax liability with 1,197 shares, increasing direct ownership by 2% to 59,594 units (SEC Form 4) to satisfy tax liability
- Chief Legal Officer Klinger Shannon Thyme converted options into 2,165 shares and covered exercise/tax liability with 1,047 shares, increasing direct ownership by 2% to 67,468 units (SEC Form 4) (tax withholding)
- President Hoge Stephen converted options into 9,282 shares and covered exercise/tax liability with 4,488 shares, increasing direct ownership by 0.32% to 1,483,848 units (SEC Form 4) to satisfy tax liability
- Moderna to Present at Upcoming Conference in June 2026
- Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting
- Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus
- Chief Financial Officer Mock James M converted options into 1,101 shares and covered exercise/tax liability with 533 shares, increasing direct ownership by 0.98% to 58,316 units (SEC Form 4) to satisfy tax liability
Latest RXRX
- Director Gibson Christopher converted options into 40,000 shares and sold $144,800 worth of shares (40,000 units at $3.62) as part of a pre-agreed trading plan (SEC Form 4)
- CEO and President Khan Najat sold $84,459 worth of shares (23,588 units at $3.58) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 2,175,796 units (SEC Form 4)
- Director Bumpus Namandje sold $15,526 worth of shares (4,386 units at $3.54) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 43,171 units (SEC Form 4)
- Director Borgeson Blake sold $110,400 worth of shares (30,000 units at $3.68) as part of a pre-agreed trading plan, decreasing direct ownership by 0.48% to 6,169,863 units (SEC Form 4)
- Recursion to Participate in Upcoming Investor Conferences
- Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
- Director Gibson Christopher converted options into 40,000 shares and sold $123,200 worth of shares (40,000 units at $3.08) as part of a pre-agreed trading plan (SEC Form 4)
- CEO and President Khan Najat covered exercise/tax liability with 62,701 shares, decreasing direct ownership by 3% to 2,199,384 units (SEC Form 4) (for withholding tax)
- Chief Scientific Officer Hallett David covered exercise/tax liability with 26,657 shares, decreasing direct ownership by 2% to 1,070,494 units (SEC Form 4) to cover withholding tax
- Director Gibson Christopher covered exercise/tax liability with 22,821 shares, decreasing direct ownership by 3% to 883,735 units (SEC Form 4) (for tax liability)